Dr. Carla Mazzeo, Ph.D.
Exosomes/EVs Scientific Governor | Expert since 2004 | MISEV Co-Author | Architecting EVs Infrastructure for Therapeutics & Regenerative | Boston & London Hubs | MedTech, Longevity
Location : Boston, Massachusetts
Speaks : English, Spanish
Dr. Carla Mazzeo is a globally recognized exosome scientist with over 20 years of expertise in extracellular vesicle (EV) research, specializing in biogenesis, characterization, and therapeutic applications.
A co-author of the MISEV2023 Guidelines, the global gold standard for EV research, Dr. Mazzeo is a leading authority in translating exosome science into clinical and commercial reality across regenerative medicine, oncology, immunology, and gastroenterology.
ABOUT ME
Dr. Mazzeo is the Founder of SAFE™ (Standards and Assessments For Exosomes/EVs), also known as the Scientific Authority for Exosome Integrity, the only independent authority governing the full lifecycle of exosome integrity, from source selection and production standards to bioactivity validation and product certification. SAFE™ provides consulting and education, comprehensive testing and characterization, process auditing, and product certification, giving manufacturers, clinics, and laboratories a verifiable gold standard backed by MISEV-level governance and over two decades of primary research.
At Boston University Medical Campus, Dr. Mazzeo founded and directs the EVs Studies Core Facility, the first of its kind dedicated to extracellular vesicles for BU and the broader Boston scientific community. She also collaborates with the Director of Gastroenterology to identify novel, non-invasive biomarkers based on exosomes for Crohn’s disease and ulcerative colitis.
Her therapeutic focus spans inflammation, oncology, immunology, gastroenterology (IBD/Crohn’s), and asthma, with applications in regenerative medicine, aesthetics, cardiovascular diseases, and infectious diseases.
EXPERIENCE
Dr. Mazzeo earned her Ph.D. in Biochemistry, Molecular Biology, and Biomedicine (Summa Cum Laude) from the Autonomous University of Madrid, with visiting research at the University of Dundee’s Wellcome Trust Biocentre. She holds certifications in Drug and Medical Device Development from MIT and Good Clinical Practice (GCP).
Her published work includes co-authorship of the MISEV2023 Guidelines and key publications in Nature Cell and Science Journal, Blood, the Journal of Extracellular Vesicles, and the Journal of Allergy and Clinical Immunology. Notably, she was the first to characterize eosinophil-derived exosomes, earning the EAACI congress abstract prize and a Special Mention from the EAACI President. She has lectured at Complutense University of Madrid and served as a subject matter expert for biotech companies.